Stock ALNY ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Alnylam Pharmaceuticals, Inc. Stock

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
247.6 USD +1.76% Intraday chart for Alnylam Pharmaceuticals, Inc. +11.09% +29.36%
Jun. 28 UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Jun. 27 Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT

Financials (USD)

Sales 2024 * 1.88B Sales 2025 * 2.3B Capitalization 30.78B
Net income 2024 * -455M Net income 2025 * -226M EV / Sales 2024 * 15.8 x
Net cash position 2024 * 1.08B Net cash position 2025 * 492M EV / Sales 2025 * 13.2 x
P/E ratio 2024 *
-68.2 x
P/E ratio 2025 *
-148 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.58%
More Fundamentals * Assessed data

Chart Alnylam Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Alnylam Pharmaceuticals, Inc.

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating MT
Out with AI, in with defensive stocks Our Logo
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating MT
More news

Latest transcript on Alnylam Pharmaceuticals, Inc.

Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Alnylam Pharmaceuticals, Inc.

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing MT
More recommendations

Press releases Alnylam Pharmaceuticals, Inc.

Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor AQ
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024 AQ
Alnylam Pharmaceuticals : HELIOS-B Topline Results Transcript PU
Alnylam Pharmaceuticals : HELIOS-B Topline Results PU
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations BU
More press releases

News in other languages on Alnylam Pharmaceuticals, Inc.

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...
ETF der Woche: Auf die Wende der Biotechs setzen
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech
More news

Quotes and Performance

1 day+1.76%
1 week+11.09%
Current month+1.90%
1 month+66.82%
3 months+61.49%
6 months+29.36%
Current year+29.36%
More quotes

Highs and lows

1 week
236.50
Extreme 236.5
252.87
1 month
147.25
Extreme 147.25
252.87
Current year
141.98
Extreme 141.975
252.87
1 year
141.98
Extreme 141.975
252.87
3 years
117.58
Extreme 117.58
252.87
5 years
69.11
Extreme 69.11
252.87
10 years
31.38
Extreme 31.38
252.87
More quotes

Managers and Directors - Alnylam Pharmaceuticals, Inc.

Managers TitleAgeSince
Yvonne Greenstreet CEO
 Chief Executive Officer 61 16-09-18
Jeffrey Poulton DFI
 Director of Finance/CFO 56 19-08-12
Piyush Sharma CMP
 Compliance Officer - 22-09-20
Members of the board TitleAgeSince
David Pyott BRD
 Director/Board Member 70 15-12-17
Charles Sigal BRD
 Director/Board Member 72 22-08-21
Margaret Hamburg BRD
 Director/Board Member 68 19-01-09
More insiders

ETFs positioned on Alnylam Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD ETF First Trust NYSE Arca Biotechnology ETF - CAD
5.08% 1 M€ -.--% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.04% 2 M€ -.--%
More ETFs positioned on Alnylam Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
24-07-02 247.6 +1.76% 1,574,207
24-07-01 243.3 +0.13% 1,491,693
24-06-28 243 -1.62% 3,246,490
24-06-27 247 +0.75% 2,617,418
24-06-26 245.2 +2.09% 2,854,588

Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT

More quotes

Company Profile

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Sector
Biotechnology & Medical Research
Calendar
2024-07-30 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
243.3 USD
Average target price
248.5 USD
Spread / Average Target
+2.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.36% 30.78B
MODERNA, INC. Stock Moderna, Inc.
+17.72% 44.44B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.33% 37.99B
LONZA GROUP AG Stock Lonza Group AG
+37.55% 37.75B
CELLTRION, INC. Stock Celltrion, Inc.
-8.44% 27.38B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.45% 26.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.19% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.93% 12.59B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.67% 11.28B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-14.77% 10.47B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALNY Stock